Form 8-K AMEDISYS INC For: Jan 30

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 30, 2017

Commission File Number: 0-24260

 

 

 

Amedisys, Inc.

(Exact name of registrant as specified in charter)

 

 

 

Delaware		11-3131700
(State or other jurisdiction of incorporation or organization)		(IRS Employer Identification No.)

3854 American Way, Suite A, Baton Rouge, LA 70816

(Address of principal executive offices, including zip code)

(225) 292-2031 or (800) 467-2662

(Registrant’s telephone number, including area code)

 

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

 

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

---

Item 7.01.

Regulation FD Disclosure.

On January 30, 2017, Amedisys, Inc. (the “Company”) issued a press release announcing the appointment of David Mikula as Chief Development Officer, a copy of which is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.

The information included in this Current Report on Form 8-K under this Item 7.01 (including Exhibit 99.1 hereto) is being “furnished” and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of Section 18, nor shall it be incorporated by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. The information included in this Current Report on Form 8-K under this Item 7.01 (including Exhibit 99.1 hereto) will not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.

 

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit Number		Description
99.1		Press Release dated January 30, 2017

---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

---

EXHIBIT INDEX

 

Exhibit Number		Description
99.1		Press Release dated January 30, 2017

		Exhibit 99.1   Contact:   Kendra Kimmons Managing Director of Communications 225-299-3708 [email protected]

Amedisys Welcomes David Mikula as Chief Development Officer

BATON ROUGE, La., Jan. 30, 2017 – Amedisys, Inc. (NASDAQ: AMED), a leading home health, hospice and personal care company, announced today that David Mikula will join the Company as Chief Development Officer, effective January 30, 2017.

Mikula has held key leadership roles across the healthcare spectrum in operations, sales and marketing, with experience ranging from occupational health and rehab services to hospitals and post-acute care. Most recently, he served as Senior Vice President and Chief Operating Officer for the Texas Region of Kindred Healthcare’s hospital division, where he was responsible for planning and directing the operational policies, objectives and initiatives for 20 sites of service with $651M in budgeted revenue.

Previously, Mikula was the Senior Vice President of Sales and Marketing for Kindred’s hospital and skilled nursing divisions, and was then promoted to Senior Vice President of Sales and Marketing for Kindred Healthcare. He was responsible for the design, drive and development of all enterprise sales activities for Kindred. His career began at Concentra, a $1 billion provider of occupational health and urgent care services.

“David is an impressive and results-oriented executive,” said President and CEO Paul Kusserow. “His depth of expertise in developing and implementing successful growth strategies and running sales and marketing teams will make him a valued addition to our leadership team.”

“This is an exciting opportunity for me,” said David. “I feel privileged to join an organization whose number-one strategy is to become the best choice for care wherever our patients call home.”

In his new position at Amedisys, Mikula will research the market to identify new opportunities for organic growth; devise a sales/business development strategy designed to achieve the Company’s revenue goals; and enhance market presence in the home health industry.

About Amedisys

Amedisys, Inc. is a leading healthcare at home Company delivering personalized home health, hospice and personal care. Amedisys is focused on delivering the care that is best for our patients, whether that is home-based personal care; recovery and rehabilitation after an operation or injury; care focused on empowering them to manage a chronic disease; or hospice care at the end of life. More than 2,200 hospitals and 61,900 physicians nationwide have chosen Amedisys as a partner in post-acute care. Founded in 1982, headquartered in Baton Rouge, LA with an executive office in Nashville, TN, Amedisys is a publicly held company. With more than 16,000 employees, in 427 care centers in 34 states, Amedisys is dedicated to delivering the highest quality of care to the doorsteps of more than 340,000 patients in need every year. For more information about the Company, please visit: www.amedisys.com.

#    #    #

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Amedisys Reports First Quarter 2024 Financial Results
• DOVRE GROUP TRADING STATEMENT JANUARY 1 – MARCH 31, 2024
• Boussard & Gavaudan Holding Ltd (GBP): Annual Report and Audited Financial Statements NSM